• Everest Medicines closed an exclusive license and collaboration agreement with Travere Therapeutics for civorebrutinib (EVER001).
• Travere will receive an upfront payment of USD 112.5 million.
• The deal includes up to USD 1.03 billion in development, regulatory, and commercial milestones across up to five indications.
• Travere is also eligible for tiered royalties ranging from high single-digit to double-digit percentages, tied to annual net sales thresholds.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Everest Medicines Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260707-12236268), on July 07, 2026, and is solely responsible for the information contained therein.